167 related articles for article (PubMed ID: 26114180)
1. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results.
Arasaradnam RP; McFarlane M; Daulton E; Westenbrink E; O'Connell N; Wurie S; Nwokolo CU; Bardhan KD; Savage RS; Covington JA
J Gastrointestin Liver Dis; 2015 Jun; 24(2):197-201. PubMed ID: 26114180
[TBL] [Abstract][Full Text] [Related]
2. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
[TBL] [Abstract][Full Text] [Related]
3. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
[TBL] [Abstract][Full Text] [Related]
4. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.
Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY
World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD).
Arasaradnam RP; McFarlane M; Daulton E; Skinner J; O'Connell N; Wurie S; Chambers S; Nwokolo C; Bardhan K; Savage R; Covington J
Dig Liver Dis; 2016 Feb; 48(2):148-53. PubMed ID: 26682719
[TBL] [Abstract][Full Text] [Related]
6. Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis--a pilot study.
Arasaradnam RP; Westenbrink E; McFarlane MJ; Harbord R; Chambers S; O'Connell N; Bailey C; Nwokolo CU; Bardhan KD; Savage R; Covington JA
PLoS One; 2014; 9(10):e107312. PubMed ID: 25330367
[TBL] [Abstract][Full Text] [Related]
7. Non-Invasive Diagnosis of Diabetes by Volatile Organic Compounds in Urine Using FAIMS and Fox4000 Electronic Nose.
Esfahani S; Wicaksono A; Mozdiak E; Arasaradnam RP; Covington JA
Biosensors (Basel); 2018 Dec; 8(4):. PubMed ID: 30513787
[TBL] [Abstract][Full Text] [Related]
8. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.
Abrigo JM; Shen J; Wong VW; Yeung DK; Wong GL; Chim AM; Chan AW; Choi PC; Chan FK; Chan HL; Chu WC
J Hepatol; 2014 Apr; 60(4):809-15. PubMed ID: 24291241
[TBL] [Abstract][Full Text] [Related]
10. Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease.
Sinha R; Lockman KA; Homer NZM; Bower E; Brinkman P; Knobel HH; Fallowfield JA; Jaap AJ; Hayes PC; Plevris JN
JHEP Rep; 2020 Oct; 2(5):100137. PubMed ID: 32775974
[TBL] [Abstract][Full Text] [Related]
11. An improved machine learning pipeline for urinary volatiles disease detection: Diagnosing diabetes.
Martinez-Vernon AS; Covington JA; Arasaradnam RP; Esfahani S; O'Connell N; Kyrou I; Savage RS
PLoS One; 2018; 13(9):e0204425. PubMed ID: 30261000
[TBL] [Abstract][Full Text] [Related]
12. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
[TBL] [Abstract][Full Text] [Related]
13. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children.
Alkhouri N; Cikach F; Eng K; Moses J; Patel N; Yan C; Hanouneh I; Grove D; Lopez R; Dweik R
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):82-7. PubMed ID: 24284369
[TBL] [Abstract][Full Text] [Related]
14. The role of ¹³C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease.
Fierbinteanu-Braticevici C; Plesca DA; Tribus L; Panaitescu E; Braticevici B
J Gastrointestin Liver Dis; 2013 Jun; 22(2):149-56. PubMed ID: 23799213
[TBL] [Abstract][Full Text] [Related]
15. Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence.
Cozzolino R; De Giulio B; Martignetti A; Forte G; Dallio M; Romeo M; Scognamiglio F; Ventriglia L; Stocchero M; Federico A
Metabolomics; 2022 Nov; 18(12):98. PubMed ID: 36441279
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath.
Verdam FJ; Dallinga JW; Driessen A; de Jonge C; Moonen EJ; van Berkel JB; Luijk J; Bouvy ND; Buurman WA; Rensen SS; Greve JW; van Schooten FJ
J Hepatol; 2013 Mar; 58(3):543-8. PubMed ID: 23142062
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
[TBL] [Abstract][Full Text] [Related]
18. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis.
Yamasaki Y; Nouso K; Miyahara K; Wada N; Dohi C; Morimoto Y; Kinugasa H; Takeuchi Y; Yasunaka T; Kuwaki K; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Iwasaki Y; Amano M; Nishimura S; Yamamoto K
J Gastroenterol Hepatol; 2015 Mar; 30(3):528-34. PubMed ID: 25168691
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single-centre bowel screening population (UK BCSP).
Mozdiak E; Wicaksono AN; Covington JA; Arasaradnam RP
Tech Coloproctol; 2019 Apr; 23(4):343-351. PubMed ID: 30989415
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
